Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240314 | 1.00 | MAPK1 (0.39) | MAPK1P2RX7SMN1; SMN2POLB | |
| SCHEMBL17667432 | 0.90 | MAPK1 (0.40) | MAPK1P2RX7 | |
| SCHEMBL27240613 | 0.90 | MAPK1 (0.40) | MAPK1P2RX7 | |
| SCHEMBL21340355 | 0.82 | USP30 (0.39) | MAPK1P2RX7SMN1; SMN2 | |
| SCHEMBL12461395 | 0.82 | USP30 (0.39) | MAPK1P2RX7SMN1; SMN2 | |
| SCHEMBL16272001 | 0.82 | USP30 (0.39) | MAPK1P2RX7SMN1; SMN2 | |
| SCHEMBL17495567 | 0.75 | MAPK1 (0.37) | MAPK1P2RX7 | |
| SCHEMBL27240479 | 0.74 | MAPK1 (0.39) | MAPK1P2RX7 | |
| SCHEMBL27240472 | 0.74 | MAPK1 (0.39) | MAPK1P2RX7 | |
| SCHEMBL1804491 | 0.74 | MAPK1 (0.36) | MAPK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-20240190868-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190868-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | MAPK1 68/4885P2RX7 3389/4885SMN1; SMN2 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.